Biotechnology, Pharmaceuticals

Join the 4th edition of BioFit on December 1st & 2nd 2015 in Strasbourg, France +1 day SPECIAL INVITATION to a Franco-German-Swiss Excellence Event on November 30th.

Vimla HUNT - 04-nov.-2015 11:12:37

  BIOFIT is the leading business convention in Europe for open Innovation, technology transfer and collaborative research in Life Sciences. More than 1300 participants will attend the 2015 edition, which will be held in Strasbourg (Alsace region), at the heart of the Franco-German-Swiss BioValley Cluster, a center of excellence for therapeutic innovation I www.biofit-event.com   Public & Private collaborations   BioFIT is the leading partnering event in Europe for Open Innovation, technology transfer and collaborative research in the field of Life Sciences, with the highest attending rate of academia, TTOs and research institutes together with big pharma, emerging and small biotech companies, medtech and diagnostics companies.   Engage new partnerships Foster the emergence of collaborative projects Intensify the flow of licenses in the field of life sciences   Who will you meet?   The event gathers leaders from pharma, biotech, medtech, IVD companies, investors, as well as professionals from technology transfer and academia.   Website : http://www.biofit-event.com/   Registration for Biofit : http://www.biofit-event.com/registration/registration-fees/  


BioValley : a French cluster dedicated to therapeutic innovations

Vimla Hunt - 27-oct.-2015 18:26:25

Alsace BioValley operates in two areas: drugs discovery and medical device. Alsace BioValley is a French cluster dedicated to therapeutic innovations, driven by Healthcare companies, for Healthcare companies. Its “pharma / biotech” and “medical technology” experts will identify new business growth opportunities, financing and innovation. They offer to Healthcare companies a range of services: funding assistance for collaborative R&D projects, coaching to fundraising, partner identification, customized relationship… Are you looking to set up a public-private R&D project to develop any therapeutic innovation ? Are you looking for a very innovative technology, patent or scientific expertise ? Here, you will discover a scientifc goldmine of researchers, companies and academic institutes. In Alsace region, you can work in partnership with great local companies or laboratories and benefit from a world of advantages! French companies in aera of medical device : clic here French companies in aera of pharmaceuticals : clic here Website : http://www.alsace-biovalley.com/en/


The success of France in biotechnologies

Marine Vicenzotti - 03-avr.-2014 12:59:26

Even though biotechnologies may be a recent sector of business activity, France has succeeded in developing real know-how that is gaining international recognition.   When it comes to biotechnologies, the French are cutting edge. According to Leeme, the federation of French medical companies, today France numbers 388 biotechs in the health field in France. Biotech France, another French association for biotech companies, indicates that a third of these companies have been in existence for over 10 years. Yet the number of creations in this field is exponential. To get an idea, 50 companies were started in 2012. Unheard of! Proof that there is a real entrepreneurial effervescence when it comes to this research in France. Young start-ups for the most part, French biotechs are mainly Small Medium sized companies. Only 4% of them have over 100 employees. On average, they employ 22 people. As to the type of activity, most of the French companies specialized in human sciences with therapeutic products are concentrated on cancer treatments. “The French have developed a full-fledged know-how on cardio-vascular devices, infectious diseases, dermatology, blood diseases and for surgery,” explains Yves Germani, Ubifrance’s manager for the health sector in North America.   French enterprises don’t just do research; they discover! Altogether, the French biotech industry generated 261 Million Euros in turnover in 2011, compared with 186 Million in 2010. As for companies on the stock market, they generate 369 Million Euros in turnover. Concerning the pipeline, the expression used to indicate the number of molecules being developed, France is 4rth, behind the United Kingdom, Germany, Switzerland and Israel. Quite a solid ranking, but which should nevertheless be improved. When their results are examined in detail, we see that depending on the stage of development, French companies create more products in the pre-clinic phase, in other words, all those that have been carried out before the clinical trial with patients, which is completely logical. Between the start of development on a new medicine, a molecule and its release on the market can sometimes take up to 10 years. Unfortunately, the consequence of this is that a number of products fall by the wayside. To be noted, however, is one undeniable fact: since 2008, French companies have sold more and more products. To put it another way, as Yves Germani points out, French companies don’t just do research; they discover!”   An increase of 63% in investment Even more impressive than all the rest, French biotech companies tend to have smaller R&D budgets than their European and international competitors. Fortunately, the culture of venture capital is developing very quickly in this sector. To give the general picture, the funds raised by French biotechs have increased by 63,1% from 2009 to 2012, reaching 178 Million Euros. Since the year 2000, they have managed to raise 2.920 Billion Euros. Today, French companies are naturally turning towards international opportunities to find new partners and new financial leverage. The proof is that such Small Medium companies as Affilogic, MedinCell, Interactive Biosoftware, Imabiotech or even O4CP all have one thing in common: they all are reaching out with confidence to mature markets like the United States, Canada and Western Europe. www.ubifrance.com/french-exporters-directory/companies.aspx   Photo: Yves GERMANI, Ubifrance New York, biotechnologies expert


Pixium Vision raises €15 million led by Sofinnova Partners

Gaëlle Leterrier - 02-déc.-2013 15:50:18

  Pixium Vision (“Pixium”), a developer of innovative retinal implant system that aims at restoring vision, has closed a €15 million Series A extension financing. This round was led by Sofinnova Partners, which becomes the largest investor, with strong support from Bpifrance, through the InnoBio fund, and existing series A investors Omnes Capital and Abingworth LLP. In conjunction with the financing, Antoine Papiernik at Sofinnova Partners and Chahra Louafi at Bpifrance have joined the Pixium Board of Directors. Pixium was co-founded by Dr Bernard Gilly and Prof. José-Alain Sahel in November 2011 and built upon a close relationship with the Vision Institute at the National Eye Hospital in Paris. With Pixium, Dr Gilly and Prof. Sahel team up one more time with Sofinnova Partners, after the success of Fovea Pharmaceuticals, a company focusing on ocular diseases they created in 2005 and successfully sold to Sanofi in 2009. The funds raised will be used to advance the development of Pixium’s IRIS retinal implant systems for patients who have lost their sight through degenerative conditions of the eye, such as retinitis pigmentosa and macular degeneration, with the intention of improving their vision. Sofinnova.fr – 25/11/2013


IPSEN strengthens its position in botulinum toxin

Consumer Goods & Life Sciences Department - 02-sept.-2013 18:56:31

The third French pharmaceutical company, Ipsen, announced the acquisition of UK-based private life sciences company, Syntaxin, specialized in botulinum toxin engineering. The two companies first started collaborating in 2010. Under the terms of the agreement, Ipsen will pay €28 million upfront, as well as further contingent payments that could reach up to €130 million or more depending on the results. The transaction fits with Ipsen’s global strategy to strengthen its core technological platforms in peptides and toxins. Syntaxin has developed considerable experience in botulinum toxin biology, supported by an extensive portfolio of patents – with 75 patents granted and over 130 patents pending ( www.syntaxin.com ) Ipsen has also recently announced a sponsored research agreement with Harvard Medical School to discover novel engineered botulinum toxins for serious neurologic diseases. This successful French company has been operating in Ireland for more than 24 years. Source: www.ipsen.com  


BPIFRANCE provides €6M to CellProthera, part of CardioStem

Consumer Goods and Life Sciences - 20-août-2013 18:37:55

On the 9th of July, CellProthera reached a new step in the development of its cell therapy, which can regenerate the heart after a severe myocardial infarction, by securing a €6M fund.he Industrial Strategic Innovation Committee of Bpifrance has recently allocated €6M to support the projects of the new consortium CardioStem, which CellProthera is part of. This collaborative project brings together Technoflex, Bertin Technologies, Streb & Weil, E3 Cortex, Research Institute of Hematology and Transplantation of Mulhouse and CellProthera. This funding comes in addition to the €8.5M of public and private funding already obtained by CellProthera within the last three years. The company is currently undergoing international clinical trials in Europe, Canada and United States. CellProthera is a leading medical biotechnology company located in Mulhouse, in eastern France, specialized in the development of autologous cell therapy for the regeneration of cardiac tissue after myocardial infarction. For further information on CellProthera, visit: www.cellprothera.com


Meet the French Biotechs delegation

Consumer Goods and Life Sciences Department - 27-mai-2013 18:42:18

UBIFRANCE Dublin and London are organising a three-day trade mission in the life sciences and healthcare sectors during the networking conference GENESIS 2013. This event, in collaboration with Bio Connect Ireland, the Irish Bio-Industry Association and One Nucleus, will take place from the 10th to 12th of December 2013 and will offer French companies the opportunity to discover and enter the Irish and British biotechnologies markets. The program of the French delegation is as followed: 10th of December: Dublin The French delegation will first visit a global biotechnology specialty care group before attending a market presentation made by experts in this field. The delegates will also have the opportunity to meet and discuss topical facts with key players in the Irish biotechnology market at a networking cocktail reception in that evening. 11th of December: London   On the second day, the French delegation will then fly to London to discover the British biotechnology market. During a visit to a pharmaceutical site, they will meet established biotechnology experts. The day will close with a networking cocktail marking the launch of GENESIS 2013.   12th of December: Genesis Conference 2013   On the 3rd day, French companies will have B2B meetings, organised through the GENESIS’s partnering platform, with key players in their area of interest within the biotechnology sector.  


About Us
The Consumer Goods and Life Sciences Department The role of the Consumer Goods & Life Sciences Department of Business France is to act as a link between French Ready-to-Wear, Cosmetics, Home interiors and Life Sciences suppliers, and existing and potential customers. We have an extensive knowledge of the French industry, which we are happy to share. We can also act as a bridge by putting you in contact with companies in your areas of interest. In order to enable Irish companies to meet with French suppliers, we organise Trade Missions all year round in Ireland.  In 2015, Business France Ireland will organise a symposium related to Telehealth. Our event in 2014 - October 1st and 2nd, 2014: Medical Devices Meetings on MEDTECH Ireland, Galway Our events in 2013 - February 13th-14th, 2013: Exclusive partnership with a major department store, Dublin - February 17th-18th, 2013: French Corner on the Hardware/DIY Home Garden Show, Dublin - April 29th, 2013: Ex

READ MORE

Facebook
Press area & Media Gallery